Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M324Revenue $M31.3Net Margin (%)-1,272.7Z-Score-7.6
Enterprise Value $M487EPS $-1.3Operating Margin %-1,075.6F-Score1
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-1,273.2Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsY
Price/Sales14.45-y EBITDA Growth Rate %0Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow6.3y-y EBITDA Growth Rate %0ROA % (ttm)-59.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-653.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M195ROI % (ttm)-57.3Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELJean-Marie Eveillard 2014-06-30 Sold Out $3.22 - $3.8
($3.45)
$ 1.66-52%Sold Out0
EXELJean-Marie Eveillard 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 1.66-76%Reduce -65.91%400,000
EXELJohn Burbank 2013-03-31 Sold Out -0.0019%$4.41 - $5.03
($4.69)
$ 1.66-65%Sold Out0
EXELJohn Burbank 2012-12-31 Buy $4.33 - $5.32
($4.79)
$ 1.66-65%New holding, 10753 sh.10,753
EXELJean-Marie Eveillard 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 1.66-69%Add 422.58%1,175,800
EXELJean-Marie Eveillard 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 1.66-68%Add 125%225,000
EXELJean-Marie Eveillard 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 1.66-67%New holding, 100000 sh.100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 1.66-77%Sold Out0
EXELJean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 1.66-83%Sold Out0
EXELJean-Marie Eveillard 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 1.66-71%New holding, 280000 sh.280,000
EXELJean-Marie Eveillard 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 1.66-76%Sold Out0
EXELJean-Marie Eveillard 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 1.66-71%New holding, 274700 sh.274,700
EXELJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 1.66-66%Sold Out0
EXELJean-Marie Eveillard 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 1.66-65%Reduce -25.67%144,800
EXELCarl Icahn 2008-12-31 Add0.19%$2.4 - $5.12
($3.8)
$ 1.66-56%Add 80.31%2,357,110
EXELJean-Marie Eveillard 2008-12-31 Add$2.4 - $5.12
($3.8)
$ 1.66-56%Add 25.84%194,800
EXELCarl Icahn 2008-09-30 Buy 0.18%$4.8 - $7.12
($6.1)
$ 1.66-73%New holding, 1307280 sh.1,307,280
EXELJean-Marie Eveillard 2008-09-30 Reduce$4.8 - $7.12
($6.1)
$ 1.66-73%Reduce -44.12%154,800
EXELJean-Marie Eveillard 2008-06-30 Add0.01%$5.07 - $7.93
($6.7)
$ 1.66-75%Add 151.82%277,000
EXELGeorge Soros 2008-06-30 Sold Out $5.07 - $7.93
($6.7)
$ 1.66-75%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71-2.92 view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-67.77 view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-64.53 view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-64.83 view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-62.19 view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-67.64 view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-80.47 view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-77.87 view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-74.46 view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-53.89 view

Press Releases about EXEL :

    Quarterly/Annual Reports about EXEL:

    News about EXEL:

    Articles On GuruFocus.com
    5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
    Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
    Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
    Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
    Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
    Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
    Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

    More From Other Websites
    Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
    Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
    Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888... Nov 16 2014
    EXELIXIS, INC. Financials Nov 14 2014
    Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
    Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
    Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
    Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
    Exelixis tops 3Q profit forecasts Nov 04 2014
    Exelixis tops 3Q profit forecasts Nov 04 2014
    Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Nov 04 2014
    Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 04 2014
    Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in... Nov 04 2014
    EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2014
    Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in... Nov 04 2014
    Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 04 2014
    EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report Nov 04 2014
    Q3 2014 Exelixis Inc Earnings Release - After Market Close Nov 04 2014
    Will Exelixis (EXEL) Disappoint This Earnings Season? Nov 03 2014
    EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 16 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK